# First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA

- Link: https://www.thailand-business-news.com/pr-news/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra
- Published: 2026-09-09T20:00:00+07:00
- Author: PR Newswire

BEIJING and BRIDGEWATER, Mass., Sept. 9, 2026 /PRNewswire/ — Gan&Lee Pharmaceuticals
Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant
has been dosed in a First-In-Human (FIH) Phase 1 study of GZC8072 tablets, a novel
ultra-long-acting oral peptide GLP-1 RA formulated for once-weekly administration.
This milestone marks the formal entry of this innovative candidate into clinical
development.

The study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled
Phase 1 study (CTR20263271), designed to evaluate the safety and tolerability of
GZC8072 in healthy adult participants in the single ascending dose (SAD) portion
and in participants with overweight or obesity in the multiple ascending dose (MAD)
portion. A total of 112 participants are planned for enrollment, and will receive
either GZC8072 tablets or matching placebo.

About GZC8072 Tablets

GZC8072 is a novel ultra-long-acting oral peptide GLP-1 RA independently developed
by Gan&Lee based on native GLP-1 and designed for once-weekly administration. It
is being developed for the treatment of type 2 diabetes mellitus (T2DM) and for 
weight management in people with obesity or overweight. GZC8072 is underpinned by
two proprietary technology platforms — **NovaPeptide™**, designed to address the
challenges of long‑acting peptide development and manufacturing, and **SupOraTide
™**, designed to overcome key barriers to oral peptide delivery. The combined use
of these platforms enables GZC8072 to achieve enhanced intrinsic activity, a prolonged
pharmacokinetic half‑life, and significantly improved oral bioavailability, supporting
a convenient once‑weekly oral dosing regimen. Currently, the global development 
program for GZC8072 tablets has progressed into Phase 1 clinical studies, with intended
therapeutic indications covering T2DM and weight management in patients with obesity
or overweight.

**Addressing Global Weight Management Needs with Oral Long-Acting Peptide Therapies**

Obesity is a chronic disease associated with a broad range of comorbidities and 
has become a major public health crisis worldwide. According to the World Health
Organization, approximately 2.5 billion adults were overweight in 2022^([1]), and
projections indicate this number will exceed 2.9 billion by 2030^([2]). In this 
context, extending the duration of action and improving dosing convenience have 
become important areas of innovation in metabolic disease R&D. The treatment landscape
is rapidly evolving – from long‑acting injectables to once-weekly oral formulations–
reflecting the demand for patient‑centric options.

**From Long-Acting Injectables to Once-Weekly Oral Formulations: Expanding Innovative
Therapies**

Gan&Lee, with extensive expertise in metabolic disorders, continues to advance its
pipeline with a focus on long-acting therapies and greater dosing convenience. Its
product portfolio continues to expand, including biweekly injectable bofanglutide(
GZR18), ultra-long-acting weekly Insulin Ludefen (GZR4), and GZC8072 tablets — a
once-weekly oral formulation that has now entered clinical development.

The clinical initiation of GZC8072 marks a key milestone for the company’s weight
management franchise. Moving forward, the company will continue to develop more 
convenient therapeutic regimens leveraging its proprietary technology platforms 
to expand treatment options for patients.

References:

1.[https://www.who.int/zh/news-room/fact-sheets/detail/obesity-and-overweight%5C#1](https://www.who.int/zh/news-room/fact-sheets/detail/obesity-and-overweight%5C#1)

2. [https://slim.medsci.cn/news/detail/be3e8660134f](https://slim.medsci.cn/news/detail/be3e8660134f)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA ](http://www.prnasia.com/story/archive/5043500_AE43500_0?rand=184833)